Resources

Explore our resources for actionable insights on data security and management

Protecting Pharmaceutical Research Data in the Age of Generative AI

A leading pharmaceutical company faced significant challenges in protecting highly sensitive research data, including drug formulas and patient trial information, as employees increasingly adopted generative AI tools for research and analysis.

Protecting Pharmaceutical Research Data in the Age of Generative AI

Challenges

In the fast-paced pharmaceutical industry, the ability to analyze vast datasets quickly is crucial for drug discovery and development. Generative AI tools offered the potential to accelerate these processes significantly. However, the company’s security team became increasingly concerned about the risk of sensitive information being inadvertently or intentionally shared with public AI models. Researchers were using these tools to summarize research papers, brainstorm new drug targets, and even analyze preliminary trial results, raising fears that confidential formulas, experimental data, and patient-identifiable information could be exposed. Existing data loss prevention (DLP) solutions were not designed to monitor interactions with generative AI platforms, leaving a significant security gap. The challenge was to enable the innovative use of AI while maintaining strict data confidentiality and adhering to stringent regulatory requirements like HIPAA.

Solutions

The pharmaceutical company implemented Fasoo AI-Radar DLP (AI-R DLP) to gain visibility and control over how generative AI was being used within the organization. AI-R DLP was deployed to monitor data being input into various generative AI services. By leveraging its pattern-matching and AI-powered content analysis capabilities, the solution could accurately identify sensitive information such as drug compound names, chemical structures (even within text prompts), clinical trial codes, and keywords associated with confidential projects. Administrators configured detailed blocking policies within AI-R DLP. These policies included:

  • Content-based blocking: Preventing the transmission of identified sensitive data patterns to generative AI interfaces.
  • User-specific controls: Implementing different levels of access and monitoring for various research teams.
  • Real-time alerts: Notifying administrators when a policy violation is detected, along with details of the user, the AI service, and the type of information involved.
  • Blocking with user notification: Displaying a pop-up message to users attempting to input sensitive data into a generative AI tool, explaining the policy violation, and guiding them toward secure data handling practices.
ico_use_case_benefits

Benefits

The implementation of Fasoo AI-Radar DLP yielded significant benefits for the pharmaceutical company:

  • Enhanced Data Security: The company gained comprehensive control over sensitive research data shared with generative AI platforms, effectively preventing accidental or malicious data leaks. Critical intellectual property and patient data remained protected.
  • Safe Adoption of Generative AI: Researchers could leverage the power of generative AI for innovation and efficiency without compromising data security, fostering a secure environment for adopting new technologies.
  • Improved Regulatory Compliance: By preventing the exposure of patient-identifiable information, the company strengthened its compliance with regulations like HIPAA, avoiding potential fines and reputational damage.
  • Increased Productivity: Clear policies and real-time feedback helped educate users on secure AI usage, minimizing disruptions caused by accidental policy violations and promoting responsible data handling.
  • Centralized Visibility and Management: The intuitive user interface of AI-Radar DLP provided administrators with a clear overview of AI usage patterns and potential risks, simplifying policy management and incident response.
List

Find out what Fasoo can do for you

Contact Us
Contact  Us
Contact Us
Keep me informed